Clinical Trial Update: Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating olaparib in combination with durvalumab for metastatic pancreatic cancer with DNA damage repair gene alterations; current stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING